



Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

November 24, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 24, 2021-- [Seres Therapeutics, Inc.](#) (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 – December 2, 2021. The fireside chat will be available for on-demand viewing on the Seres website.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent *C. difficile* infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit www.serestherapeutics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211124005642/en/): <https://www.businesswire.com/news/home/20211124005642/en/>

PR

Kristin Ainsworth
kainsworth@serestherapeutics.com

IR

Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com

Source: Seres Therapeutics, Inc.